NCT07589036Completed
Effects of Dioscorea Yam Gruel on Blood Lipid Profiles in PCI Patients With Coronary Heart Disease
Effects of Dioscorea Yam Gruel on Blood Lipid Profiles in PCI Patients With Coronary Heart Disease: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
This randomized controlled trial investigated the effects of Dioscorea yam gruel on blood lipid levels in patients with coronary heart disease after percutaneous coronary intervention (PCI). A total of 72 eligible post-PCI patients were randomly assigned to the control group or the intervention group. Patients in the control group received standard post-procedural treatment and care. In addition to this standard regimen, those in the intervention group were provided with approximately 150 g of Dioscorea yam gruel daily as a partial dinner replacement for 12 consecutive weeks. Serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and body mass index (BMI) were measured at baseline, and at 8 weeks and 12 weeks of the intervention.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 5 May 2026
- Start date
- 10 Jan 2024
- Primary completion date
- 15 Mar 2025
- Lead sponsor
- 900th Hospital of PLA Joint Logistic Support Force
- Diseases
- Coronary artery disease
- NCT number
- NCT07589036
What you commit to
- Study type: Interventional
- Participants enrolled: 72
- From 10 Jan 2024 to the primary completion date, 15 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Complicating with other severe diseases or diseases that affect blood lipid levels, such as malignant tumors, acute cerebrovascular disease, nephrotic syndrome, severe liver disease, Cushing's syndrome, and others
Lab values
- Low-density lipoprotein cholesterol (LDL-C) level \< 70 mg/dL(\<1.81mmol/L) at screening
Other
- Pregnancy or lactation
- Concurrently participating in other dietary or exercise intervention programs
Who the study is looking for
- Meeting the diagnostic criteria for coronary heart disease (2020 edition)
- Undergoing percutaneous coronary intervention (PCI)
- Aged between 18 and 75 years
- Having been on a stable dose of statin therapy for at least 4 weeks prior to screening
- Being in a stable clinical condition, conscious, providing informed consent, and participating voluntarily
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 900th Hospital of PLA Joint Logistic Support Force Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.